Aurobindo Targets $2B Revenue, EBITDA Margin Above 21%

Aurobindo Pharma Limited — Q4 FY26 Earnings Call (22 May 2026)

1. Overall Tone of Management: Optimistic

• Management repeatedly emphasizes “excellent quarter” and “strong financial year,” citing “highest-ever revenues and highest-ever EBITDA.”
• Forward-looking language is confident: “we remain encouraged,” “we firmly believe,” “aiming to touch the $2 billion revenue milestone over the near term,” and “EBITDA margins… progressively improve to north of 21%.”
• Even when discussing risks (e.g., US FTC timing, geopolitical issues), responses are framed as manageable (“we feel fairly confident,” “taken it bit conservatively but we are confident”).

2. Key Themes from Management Commentary

• Consolidated performance at record levels
• FY26: Revenue ₹33,653 cr, EBITDA ₹6,856 cr, EBITDA margin 20.4% (highest-ever).
• Q4: Revenue ₹8,853 cr, EBITDA margin 20.3%.
• Growth drivers: volumes + new launches + regulated market momentum
• “stable volumes, new product launches and sustained momentum in regulated markets supported by pricing conditions.”
• US business: gRevlimid normalization creates reported softness, but pipeline/acquisitions are the growth engine
• US formulations flat in quarter; constant currency US revenue down 18% YoY due to high gRevlimid in Q4 FY25.
• Management leans on base expansion + new launches + Lannett acquisition and pipeline from Dayton/Raleigh.
• Europe: strong momentum and confidence in continued growth
• Q4 Europe +30% YoY; FY26 milestone: €1 billion annual revenue.
• Guidance in Q&A: “minimum double digit” growth (constant currency), with China tech-transfer contributing.
• Pen-G / 6-APA / Amoxy backward integration: margin improvement via captive inputs
• Power/fuel cost spike explained by Pen-G ramp; gross margin improved ~100 bps.
• External Pen-G sales already started: “sold more than ₹100 crores worth… in the last quarter.”
• Production visibility: annualized Pen-G output expected to exceed 10,000 MT with >80% utilization (based on current operating levels).
• Biosimilars/biologics CMO: long-term runway with defined milestones
• Biosimilars: discussion of product pipeline and “inflection point” by 2030.
• CDMO (TheraNym): Unit-1 revenue expected to begin 2028; Unit-2 2031 (calendar-year framing corrected later).
• Cash generation and capital discipline
• Net cash position improved to $317m (from $276m in Dec’25), despite acquisition consideration payments.
• Capex: net CapEx Q4 $82m, FY ~$341m.

3. Q&A Analysis

Theme A: Cost structure / Pen-G ramp-up economics

• Core questions
• Why operating costs rose (power/fuel vs one-offs)?
• Whether cost rate continues; how Pen-G affects gross margin.
• Pen-G/6-APA EBITDA losses and breakeven timing; external sales timing.
• Management response
• Cost increase mainly due to “power and fuel consumption for the Pen-G plant” ramping up.
• Rate expected to continue: captive 6-APA use reduces imported raw material cost while other expenses rise; gross margin improved accordingly.
• FY26 losses: Pen-G + 6-APA incurred ~₹200 cr+ EBITDA loss last year; China facility loss expected to turn profitable EBITDA contribution this year.
• External Pen-G sales: already happened in the last quarter, >₹100 cr sold; expects offtake to strengthen.
• Red flags / evasiveness
• Some financial specificity is provided (₹200 cr+ loss), but no clean FY27 “burn” number; relies on qualitative “positive contribution” and “better yields.”

Theme B: US growth targets, Lannett deal timing, and base business trajectory

• Core questions
• Timeline to reach $2B US revenue milestone.
• Is $2B driven mainly by Lannett?
• Status/timing of FTC approval and deal close.
• Growth of base US business ex-acquisitions.
• Management response
• $2B: “probably… in the next maybe couple of years”; could be faster “if acquisitions materialize.”
• Lannett close: “close by Q2 of the current fiscal,” with timing risk from FTC government shutdown (76 days); “early Q2 may be a better estimate.”
• Base growth: cannot give exact timing; expects to “touch that $2 billion goal” with Lannett part of it; business development/in-licensing/ANDA acquisitions mentioned.
• Notable strength
• Clear explanation of FTC delay cause (government shutdown) and confidence language (“fairly confident”).
• Evasiveness
• Base business growth ex-acquisition not quantified; “timing wise, I cannot tell you for certain.”

Theme C: Europe growth outlook and China contribution

• Core questions
• After reaching €1B milestone, how Europe grows from here (growth rate, FY27 outlook).
• How China supply ramp should translate into Europe growth.
• Management response
• “definitely bullish,” confident to move northwards.
• China contribution: “more than 10 products have kicked in… progressively… increase and contribute.”
• Growth target: “trying to achieve double digit growth… minimum double digit,” with geopolitical conservatism.
• Clarified in follow-ups: growth is constant currency.
• No major evasiveness
• Provides a directional range (double-digit; minimum double digit) rather than exact %.

Theme D: CDMO / biologics commercialization timelines

• Core questions
• When biological CDMO starts commercializing; first revenue timing for Unit-1 and Unit-2.
• Whether timelines are calendar vs financial year.
• Management response
• Unit-1 commissioned end of year; first revenue stream begins 2028 (Unit-1 head start).
• Unit-2 revenue start 2031; between Unit-1 and Unit-2 revenues kick in from 2031 (later corrected: calendar years, and earlier “2028/2031” were calendar).
• Red flag
• Calendar vs financial year confusion required a correction at the end—minor credibility hit.

Theme E: Biosimilars strategy, product count, and margins under price erosion

• Core questions
• Biosimilar “FY30 vision”: number of products, geography spread, milestones.
• Ability to make reasonable revenues despite being behind competition in Europe/emerging markets.
• Expected gross margin range and built-in price erosion assumptions.
• Management response
• Product count by 2030: 7–8 products in Europe/growth markets + potentially 2–3 in US; “inflection point” by 2030.
• “First wave” framing: opportunity is relevant but not targeting 15–20% market share; focus on COGS competitiveness and longer-life-cycle products.
• Margin: US gross margin ~65–70%, potentially 70–75% as mix matures; price erosion assumptions: US ≤60%, Europe ~75–85%; still targeting ~65% gross margin even after heavy erosion.
• Strong admissions
• Explicitly acknowledges competitive intensity and price erosion dynamics; provides modeling logic (yield vs COGS, capacity scale, yields 4–6 g/L).

Theme F: FX translation and FY27 margin guidance assumptions

• Core questions
• How much INR depreciation helps EBITDA; whether FY27 21% margin bakes in FX positives.
• Management response
• 1% INR depreciation vs USD: ~₹100 cr EBITDA.
• FY27 21% margin: “Don’t look into that” (i.e., not a simple FX-only assumption); management emphasizes offsetting cost inflation (solvent/raw materials/freight).
• Credibility signal
• Pushes back on simplistic FX attribution; frames holistic cost pressures.

4. Guidance / Outlook

Explicit guidance (quantitative)

• FY27 EBITDA margin: “sustain and progressively improve to north of 21%.”
• Pen-G production: annualized Pen-G production to exceed 10,000 MT with capacity utilization >80% (based on current operating levels).
• Europe growth (directional quantitative): “minimum double digit” (constant currency) after €1B milestone.
• US revenue milestone: aim to “touch the $2 billion revenue milestone over the near term” (timeline not fixed; “couple of years”).
• CDMO revenue timing (calendar-year framing corrected):
• Unit-1 revenues begin 2028
• Unit-2 revenues begin 2031
• Biosimilars margin modeling (qualitative with ranges):
• US gross margin 65–70%, potentially 70–75% with mix maturity.

Implicit signals (qualitative)

• US: growth levers include base expansion, new launches, Lannett, pipeline expansion; management expects FTC approval and deal close but acknowledges timing risk.
• Europe: confidence in momentum despite “geopolitical issues.”
• Pen-G: external sales already started; management expects offtake to strengthen “coming days, coming weeks.”
• Capital allocation: “prudent capital allocation,” no major greenfield beyond biologics/CDMO; selective M&A/in-licensing.

5. Standout Statements (direct quotes where useful)

• Record performance
• “highest-ever revenues and highest-ever EBITDA”
• US milestone ambition
• “aiming to touch the $2 billion revenue milestone over the near term”
• “probably in the next maybe couple of years”
• Lannett timing
• “close by Q2 of the current fiscal… government closure for 76 days… FTC does not function”
• Europe confidence
• “we are definitely bullish… moving northwards”
• “minimum double digit” growth (constant currency)
• Pen-G external commercialization
• “external supply has already been happened in the last quarter… sold more than ₹100 crores”
• Pen-G production visibility
• “annualized production, Pen-G production, to exceed 10,000 metric tons… utilization exceeding 80%”
• FY27 margin
• “EBITDA margins… progressively improve to north of 21%”
• CDMO revenue timing
• “steady stream of revenues… would begin in Unit-1 from 2028… Unit-2… 2031”
• Later correction: “calendar years and not financial year”
• Biosimilars competitive stance
• “we are not looking at a 15%-20% market share”
• “COGS model… to still give you a reasonable margin”
• FX guidance pushback
• “Don’t look into that [FX]… nothing comes free… raw material prices… solvent prices… freight cost…”

6. Red Flags / Positive Signals

Red flags
– Calendar vs financial year confusion on CDMO revenue timing required a correction (“apologies”); suggests potential for timeline communication slippage.
– US $2B milestone remains loosely timed (“couple of years,” “if acquisitions materialize”)—depends on regulatory approvals and business development execution.
– Limited quantitative disclosure on FY27 segment-level EBITDA/burn for ramping projects (Pen-G, China, Eugia-related items).

Positive signals
– Pen-G external sales already underway (>₹100 cr in Q4) rather than purely internal consumption story.
– Clear explanation for cost spike (power/fuel) and linkage to gross margin improvement.
– Margin guidance specificity (north of 21% EBITDA margin for FY27).
– Biosimilars margin framework includes explicit price erosion assumptions and yield/COGS logic.

7. Historical Comparison & Consistency Analysis (vs prior 3 calls)

a. Change in Tone Over Time

• Current (Q4 FY26): More Optimistic
• Stronger “record” framing and confident margin outlook (“north of 21%”).
• Prior calls
• Q3 FY26 (Feb 2026): confident but more conditional; emphasized execution and “visibility,” still discussing ramp-up and policy catalysts.
• Q2 FY26 (Nov 2025): optimistic but more about ramp-up milestones (Pen-G, China, biosimilars commercialization readiness).
• Q4 FY25 (May 2025): optimistic with margin stability targets; more emphasis on “tariff announcements” and normalization.
• Shift drivers
• Pen-G and Europe momentum appear more “realized” now (external sales started; €1B Europe milestone achieved).
• Management is more willing to give quantitative FY27 margin guidance now than earlier.

b. Tracking Past Commitments vs Outcomes

• Pen-G ramp / production >10,000 MT
• Past (Q3 FY26 Feb 2026): “expect to produce more than 10,000 metric tonnes on annualised basis over the next 12 months.”
• Current (Q4 FY26 May 2026): expects annualized Pen-G production exceed 10,000 MT with >80% utilization.
• Status: ✅ On track / reiterated with more operational detail (also shows external sales).
• Europe milestone
• Past (Q3 FY26 Feb 2026): “trajectory to exceed 1 billion annual European revenue by close of FY26.”
• Current: “Europe… achieved… milestone of €1 billion revenue in terms of annual revenues.”
• Status: ✅ Delivered.
• US Lannett close timing
• Past (Q3 FY26 Feb 2026): FTC approval expected “early in the next fiscal year, that is Q1 of ‘27.”
• Current: close “by Q2 of the current fiscal” with delay explanation (76-day government shutdown).
• Status: ⏳ Delayed (from Q1 ‘27 expectation to early Q2 estimate).
• CDMO revenue timing
• Past (Q4 FY25 May 2025 / earlier): TheraNym commissioning and revenue timing discussed broadly (revenues expected from following fiscal).
• Current: more specific: Unit-1 revenue 2028, Unit-2 2031, but with calendar/financial-year correction.
• Status: ⏳ More defined but communication needed correction.

c. Narrative Shifts

• From “ramp-up and readiness” to “commercialization and milestones”
• Pen-G moved from internal ramp expectations to external sales already happening.
• Europe moved from “on track” to milestone achieved.
• US narrative increasingly acquisition/pipeline dependent
• With gRevlimid normalization, management leans more on Lannett + business development rather than organic US growth alone.
• CDMO/biosimilars narrative becomes more structured
• More explicit product counts, margin ranges, and unit-by-unit revenue timelines.

d. Consistency & Credibility Signals

• Medium credibility (improving, but not perfect)
• Strength: consistent emphasis on Europe momentum and Pen-G operational ramp.
• Weakness: timeline precision issues (CDMO calendar vs financial year; Lannett timing moved).
• Management explanations are generally coherent (e.g., FTC shutdown reason), which supports credibility.

e. Evolution of Key Themes

• Margins / profitability
• Improving trajectory: gross margin and EBITDA margin highlighted repeatedly; FY27 “north of 21%” is a step-up in specificity.
• Europe growth
• Stable-to-improving: from high-teens growth discussions to €1B milestone and “minimum double digit” outlook.
• US growth
• More volatile: gRevlimid-driven comparability issues; reliance on acquisitions and pipeline.
• Pen-G backward integration
• Theme matured: from ramp-up and policy catalyst to external sales + production visibility.
• Biosimilars
• From approvals/readiness to product count + margin/price erosion modeling and “inflection point” framing.

f. Additional Insights (Cross-Period Intelligence)

• Risk build-up is now more explicit in execution dependencies
• US growth depends on FTC timing and business development deals; management acknowledges “timing wise, I cannot tell you for certain.”
• Operational wins are being converted into narrative confidence
• External Pen-G sales and Europe milestone achievement reduce prior “promise risk,” supporting the more optimistic tone.
• Communication precision is slightly weaker in long-dated projects
• CDMO timeline correction suggests that while milestones are being defined, internal framing (calendar vs fiscal) can slip—important for long-dated revenue modeling.